Telehealth’s Weight Loss Dreams Deflate As FDA Ends Drug Shortage Status
The FDA just pulled the plug on telehealth’s weight-loss gold rush. After abolishing GLP-1 drug semaglutide’s shortage status, the agency patched a loophole that let low-cost rivals produce cheaper Ozempic and Wegovy alternatives — erasing billions from would-be disruptors’ stocks as big pharma tightens its grip on loosening belts.
- The shortage of Ozempic and Wegovy’s key ingredient, semaglutide, permitted competitors to sell $200 “compounded” alternatives vs. $1K for the brand-name drugs — but the FDA will eradicate this loophole within 90 days.
- The ruling impacts Hims & Hers and Lemonaid Health, whose stocks tumbled 29.4% and 16.7% this weekend, respectively — despite Ozempic and Wegovy’s owner, Novo Nordisk, expecting “continued periodic supply constraints.”
Strategic shifts in weight loss: Platforms are already racing to adapt — Hims & Hers acquired blood testing startup Trybe Labs to expand diagnostics, while Ro, another compounded semaglutide distributor, partnered with Eli Lilly to offer discounted vials of another GLP-1, Zepbound. Meanwhile, Lilly plans to reinvest its obesity drug windfall into ambitious research targets like Alzheimer’s and ALS, positioning itself as healthcare’s new heavyweight. For telehealth disruptors, the FDA’s reality check means it’s time to shape up or ship out.
